Nairobi, Kenya — HIV prevention in Kenya has received a major boost with the arrival of 21,000 doses of a long-acting injectable HIV prevention drug, officials confirmed Wednesday. The shipment represents a critical step in expanding access to pre-exposure prophylaxis (PrEP) for populations at heightened risk of HIV infection.
The injectable PrEP, administered once every two months, offers a convenient and discreet alternative to daily oral pills. Health experts say this innovation could significantly improve adherence rates, particularly among young women and key populations who face challenges in maintaining a daily medication routine.
“This delivery expands the range of prevention choices available to Kenyans and strengthens our fight against new HIV infections,” said a senior Ministry of Health official. “It also comes at a time when awareness and prevention efforts are more crucial than ever.”
The rollout coincides with heightened public concern following reports that a Russian national named Yaytseslav is under investigation for allegedly exposing more than 100 Kenyan women to HIV. Authorities have emphasized that investigations are ongoing and no formal court determinations have been made. The case has triggered renewed calls for regular HIV testing, responsible disclosure, and broader access to preventive tools.
Health experts stress that the incident highlights the critical importance of early detection, preventive measures, and public education. They also note that individuals living with HIV who adhere to antiretroviral therapy (ART) and maintain an undetectable viral load cannot transmit the virus — a principle known as “Undetectable = Untransmittable” (U=U).
The long-acting injectable PreEP has been recommended by the World Health Organization as an additional prevention option for individuals at substantial risk of HIV. Kenya is integrating the injectable option into its national HIV prevention programs as part of a comprehensive strategy combining testing, treatment, and community awareness campaigns.
Government statistics indicate Kenya has made remarkable progress in reducing AIDS-related deaths and expanding access to life-saving ART, which is available free at public health facilities. Despite these gains, thousands of new infections continue to be recorded annually, particularly among young women and key populations in high-prevalence counties.
Officials said the 21,000 doses will initially be distributed to counties with the highest HIV prevalence before a phased nationwide rollout. Healthcare workers are receiving training on patient eligibility, administration protocols, and follow-up monitoring to ensure safe and effective delivery.
Civil society organizations welcomed the new prevention tool, describing it as a timely intervention that could substantially reduce new infections if widely implemented. They also emphasized the importance of sustained public awareness campaigns, consistent funding, and strong measures to combat stigma and misinformation.
In addition to expanding access to injectable PrEP, health authorities are calling on communities to continue using preventive measures such as condoms, voluntary testing, and responsible disclosure. These combined efforts are critical to strengthen HIV prevention in Kenya and reduce the risk of new infections.
As investigations into the alleged exposure case continue, health authorities reaffirm that prevention remains the most effective tool. The introduction of long-acting injectable PrEP strengthens HIV prevention in Kenya, protecting vulnerable populations and supporting the government’s goal of eliminating new infections by 2030.
By combining innovative prevention tools with ongoing treatment programs, public education, and community awareness campaigns, Kenya is aiming to reduce HIV transmission rates, improve health outcomes, and safeguard the well-being of all its citizens.
